Our People
Mon, Dec 16, 2024 9:37 AM

Egis Pharmaceuticals Plc. Expands Its Portfolio with a Well-Known Product Line

Egis Pharmaceuticals has announced that, backed by the Hungarian Competition Authority´s official certification, it has acquired one of Hungary´s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd. This move aims to strengthen Egis´s position in the Hungarian over-the-counter (OTC) market.
Our People

Egis Pharmaceuticals Plc. Expands Its Portfolio with a Well-Known Product Line

Egis Pharmaceuticals has announced that, backed by the Hungarian Competition Authority´s official certification, it has acquired one of Hungary´s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd. This move aims to strengthen Egis´s position in the Hungarian over-the-counter (OTC) market.
Mon, Dec 16, 2024 9:37 AM
Author:
Mon, Dec 16, 2024 9:37 AM
Author:

Egis has previously marketed locally applied dermatological products, and with this acquisition, the company seeks to expand this portfolio further. 
 
"The production of the flagship medicine in this newly acquired product line will be brought back to Hungary. Following a successful technology transfer, it will be manufactured at Egis's recently inaugurated, state-of-the-art galenical plant in Körmend," added Csaba Poroszlai, CEO of Egis, in the announcement. 
 
Egis Pharmaceuticals is a pharmaceutical company with more than 110 years of history, headquartered in Hungary, and equipped with facilities for active ingredient and drug manufacturing. Its activities cover all value-creating processes of the pharmaceutical industry, from research and development to the production of active ingredients and finished products, as well as sales. 
 
Teva Pharmaceutical Industries Ltd. has decided to divest this product line as part of its global business strategy and will focus on other global, locally applied dermatological brands in the future. 
 
The transition of marketing and promotion for the product line will take place on December 17, 2024. As part of the transaction, both parties have worked to ensure continuous product availability for consumers. 
 

#production #products #pharma
Related articles from Egis Magazine
Egis World

Agreement for Biosimilar Candidates in Key Central and Eastern European Markets
More
Innovation

Egis' medicines won the Innovation Grand Prize
More
Innovation

Egis expands its portfolio with active pharmaceutical ingredient contract development and contract manufacturing
More

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox